ANADYS PHARMACEUTICALS INC 4/A
4/A · ANADYS PHARMACEUTICALS INC · Filed Jun 7, 2005
Insider Transaction Report
Form 4/AAmended
HBM BIOVENTURES AG
10% Owner
Transactions
- Sale
Common Stock
2005-06-02$8.00/sh−400$3,200→ 2,717,755 total(indirect: By HBM BioVentures (Cayman) Ltd.) - Sale
Common Stock
2005-06-02$8.11/sh−2,400$19,464→ 2,703,555 total(indirect: By HBM BioVentures (Cayman) Ltd.) - Sale
Common Stock
2005-06-02$8.37/sh−1,700$14,229→ 2,664,605 total(indirect: By HBM BioVentures (Cayman) Ltd.) - Sale
Common Stock
2005-06-02$8.14/sh−2,300$18,722→ 2,701,255 total(indirect: By HBM BioVentures (Cayman) Ltd.) - Sale
Common Stock
2005-06-02$8.32/sh−4,200$34,944→ 2,676,205 total(indirect: By HBM BioVentures (Cayman) Ltd.) - Sale
Common Stock
2005-06-02$8.01/sh−1,000$8,010→ 2,716,755 total(indirect: By HBM BioVentures (Cayman) Ltd.) - Sale
Common Stock
2005-06-02$8.04/sh−2,000$16,080→ 2,713,555 total(indirect: By HBM BioVentures (Cayman) Ltd.) - Sale
Common Stock
2005-06-02$8.10/sh−6,300$51,030→ 2,705,955 total(indirect: By HBM BioVentures (Cayman) Ltd.) - Sale
Common Stock
2005-06-02$8.15/sh−3,900$31,785→ 2,697,355 total(indirect: By HBM BioVentures (Cayman) Ltd.) - Sale
Common Stock
2005-06-02$8.39/sh−600$5,034→ 2,661,705 total(indirect: By HBM BioVentures (Cayman) Ltd.) - Sale
Common Stock
2005-06-02$8.41/sh−6,080$51,133→ 2,650,825 total(indirect: By HBM BioVentures (Cayman) Ltd.) - Sale
Common Stock
2005-06-02$8.40/sh−4,800$40,320→ 2,656,905 total(indirect: By HBM BioVentures (Cayman) Ltd.) - Sale
Common Stock
2005-06-02$8.42/sh−800$6,736→ 2,650,025 total(indirect: By HBM BioVentures (Cayman) Ltd.) - Sale
Common Stock
2005-06-02$8.05/sh−1,300$10,465→ 2,712,255 total(indirect: By HBM BioVentures (Cayman) Ltd.) - Sale
Common Stock
2005-06-02$8.25/sh−1,750$14,438→ 2,689,655 total(indirect: By HBM BioVentures (Cayman) Ltd.) - Sale
Common Stock
2005-06-02$8.33/sh−2,200$18,326→ 2,674,005 total(indirect: By HBM BioVentures (Cayman) Ltd.) - Sale
Common Stock
2005-06-02$8.26/sh−100$826→ 2,689,555 total(indirect: By HBM BioVentures (Cayman) Ltd.) - Sale
Common Stock
2005-06-02$8.29/sh−1,400$11,606→ 2,688,155 total(indirect: By HBM BioVentures (Cayman) Ltd.) - Sale
Common Stock
2005-06-02$8.36/sh−3,800$31,768→ 2,666,305 total(indirect: By HBM BioVentures (Cayman) Ltd.) - Sale
Common Stock
2005-06-02$8.43/sh−3,050$25,712→ 2,646,975 total(indirect: By HBM BioVentures (Cayman) Ltd.) - Sale
Common Stock
2005-06-02$7.94/sh−2,100$16,674→ 2,718,155 total(indirect: By HBM BioVentures (Cayman) Ltd.) - Sale
Common Stock
2005-06-02$8.21/sh−1,600$13,136→ 2,694,455 total(indirect: By HBM BioVentures (Cayman) Ltd.) - Sale
Common Stock
2005-06-02$8.02/sh−1,200$9,624→ 2,715,555 total(indirect: By HBM BioVentures (Cayman) Ltd.) - Sale
Common Stock
2005-06-02$8.22/sh−1,850$15,207→ 2,692,605 total(indirect: By HBM BioVentures (Cayman) Ltd.) - Sale
Common Stock
2005-06-02$8.30/sh−6,450$53,535→ 2,681,705 total(indirect: By HBM BioVentures (Cayman) Ltd.)
Footnotes (2)
- [F1]HBM BioVentures AG (the "Reporting Entity") is the sole shareholder of HBM BioVentures (Cayman) Ltd. ("HBM"), the entity that owns the reported securities.
- [F2]The Reporting Entity is the sole shareholder of HBM which owned 1,844,418 shares of Anadys Pharmaceuticals, Inc. (the "Company") prior to the transactions reported herein. The Reporting Entity is also the sole shareholder of Biomedicine AG, which is the sole shareholder of International BM Biomedicine Holdings (Cayman) Ltd. which is the general partner of Biomedicine L.P. that owns 875,837 shares of the Company. The Reporting Entity disclaims beneficial ownership of these shares in excess of its pecuniary interest therein.